Skip to Main Content

Paper Details

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol
10
2021
Bev, CPT, CRLX101, Patients, Pts, Topoisomerase-1, anemia, bevacizumab, bladder toxicities, camptothecin, cancer, cancer cells, epithelial ovarian, tubal or primary peritoneal cancer, fatigue, hypertension, nausea, ovarian cancer, platinum, pts, topo-1, topoisomerase I
Author NameAffiliation
Hang LeeMassachussetts General Hospital
Michael J BirrerUniversity of Arkansas
  • 1 - 2

Datasets

Release 1.2